Descrizione del progetto
Rilevare forme tumorali precoci grazie a sonde specifiche per i glicani
Lo sviluppo del cancro è un processo a più fasi e la scoperta del tumore in una fase iniziale, quando il cancro è ancora curabile, richiede strumenti diagnostici sensibili ed efficaci. Il progetto GlycoImaging, finanziato dalle azioni Marie Skłodowska-Curie, intende sviluppare e implementare nuovi test per il rilevamento dei glicani come biomarcatori associati a tumori metastatici aggressivi nel sangue, nelle urine, nelle cellule e nei tessuti. Il progetto prevede la formazione di 8 specialisti della ricerca delle fasi tumorali iniziali da parte di un consorzio composto da 6 partner del mondo accademico e industriale con competenze biomediche, di imaging e di sintesi di particelle. L’obiettivo del progetto è fornire le basi per un programma di formazione interdisciplinare di alta qualità destinato all’istruzione e alla ricerca.
Obiettivo
The overall objective of Glyco Imaging is to develop novel assays for detection of glycans as biomarkers associated with aggressive and metastatic cancer forms. The assays will be developed for biomarker detection in blood, urine, cells and tissue. Molecularly Imprinted Polymers (MIPs), or plastic antibodies, have been developed for targeting the human glycan sialic acid (SA), or Neu5Ac. The efficiency of the Neu5Ac specific SAMIPs targeted to the biomarker SA in different solvents (methanol, water, phosphate buffer) will be exploited. The non-human Neu5Gc, which is incorporated into human glycoconjugates through dietary sources such as red meat, and shown to be involved in malignant cell transformation in humans, will also be investigated by using highly specific Neu5Gc-SAMIPs. The imaging and detection techniques used will be based on fluorescence, 3D-viewing of cancer cells by digital holographic microscopy and magnetic separation columns.
The results in this research consortium will lead to major technological advances having impact on 1) health care, since it will develop more accurate and reliable diagnostics of aggressive and metastatic cancers, 2) drug discovery allowing a faster and cheaper biomarker targeting and detection; and 3) biochemistry research laboratories in resulting in improved understanding of glycan expression in cancer, with emphasis on aggressive metastatic cancer. The training of researchers will be performed by a consortium consisting of 6 partners with biomedical, imaging and particle synthesis skills (4 groups, one institution, one technology company). This forms the basis for a very competent interdisciplinary training program with high quality in both education and research.
8 early stage researchers (ESRs) working on specific tasks within 5 work packages will follow a rich training program providing a well-balanced spectrum of scientific, business and entrepreneurial skills.
Campo scientifico
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesphysical sciencesopticsmicroscopy
- natural sciencesbiological sciencesbiochemistrybiomoleculescarbohydrates
- medical and health sciencesclinical medicineoncology
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-ITN-ETN - European Training NetworksCoordinatore
205 06 Malmoe
Svezia